Global Epidemiology on Colistin Resistant Acinetobacter baumanniiSalman Shaheer Ahmed1*, Emine Alp1, Joost Hopman2 and Andreas Voss2
- *Corresponding Author:
- Salman Shaheer Ahmed
Department of Infectious Diseases
Faculty of Medicine, Erciyes University
Tel: +90 531 381 9526
E-mail: [email protected]
Received date: June 27, 2016; Accepted date: July 05, 2016; Published date: July 07, 2016
Citation: Ahmed SS, Alp E, Hopman J, Voss A (2016) Global Epidemiology on Colistin Resistant Acinetobacter baumannii. J Infect Dis Ther 4:287. doi:10.4172/2332-0877.1000287
Copyright: © 2016 Ahmed SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
While colistin remains a last resort agent to treat multi-drug resistant Acinetobacter baumannii, resistance to colistin has been reported throughout the world. The resistance has been attributed to mutations in lipid A biosynthesis genes and point mutation in PmrAB-two component response regulator and sensor kinase system. The emergence of plasmid mediated colistin resistance (mcr-1), in multidrug-resistant enterobacteriaceae raised concerns, though mcr-1 has not yet been reported in A. baumannii. Lately, colistin resistance has been attributed to efflux pumps belonging to RND family. While various reports of emergence of colistin resistance are associated with previous treatment with colistin, other reports concern patients without any prior therapy.